Giulia D'ARcangelo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Giulia D'ARcangelo has a total of 126 co-authors. Here are the top co-authors by number of shared publications:
- Marina Aloi
Department of Pathophysiology and Transplantation University of Milan Milan Italy
8 shared publications - Fortunata Civitelli
Pediatric Gastroenterology and Liver Unit, Sapienza University of Rome, Rome, Italy
4 shared publications - Massimo Martinelli
Department of Translational Medical Science, Section of Pediatrics, University of Naples "Federico II", Naples, Italy
4 shared publications - Matteo Bramuzzo
Institute for Maternal and Child Health - IRCCS “Burlo Garofolo”, Trieste, Italy
4 shared publications - Simona Gatti
Department of Pediatrics Polytechnic University of Marche Ancona Italy
4 shared publications Giovanna Zuin
Pediatric Department Fondazione IRCCS San Gerardo dei Tintori Monza Italy
3 shared publications
Latest Publications
- 12 November 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
Pediatric inflammatory bowel diseases in patients with genetic syndromes: A case–control multicentre SIGENP study
Objectives: To characterize the clinical phenotype and long‐term outcomes of pediatric inflammatory bowel disease (IBD) in patients with genetic syndromes. Methods: Multicenter observational case‐control study using data from the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition IBD registry. Patients diagnosed with pediatric‐onset IBD (p = 0.004) and height (−1.43 z ‐score, p < 0.001); these differences persisted at follow‐up. Diagnostic delay was longer in syndromic patients (+6.5 months, p = 0.045). Abdominal pain was less frequent at presentation ( p = 0.01). Syndromic patients had more hospitalizations (IBD‐related incidence rate ratio [IRR] 1.23, p = 0.033; non‐IBD IRR 1.65, p < 0.001), more comorbidities (odds ratio [OR] 18.2, p < 0.001), and greater use of non‐IBD medications (OR 8.17, p = 0.004). The risk of additional autoimmune diseases was higher but not statistically significant. Conclusions: Pediatric IBD patients with genetic syndromes show impaired growth and delayed diagnosis, while intestinal disease activity and treatment exposure are comparable to non‐syndromic peers. The higher burden of comorbidities and hospitalizations indicates greater healthcare complexity and diagnostic challenges; early recognition and coordinated multidisciplinary care are reasonable clinical considerations, but their impact on outcomes requires prospective evaluation.
- 12 November 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
Pediatric inflammatory bowel diseases in patients with genetic syndromes: A case–control multicentre SIGENP study
Objectives: To characterize the clinical phenotype and long‐term outcomes of pediatric inflammatory bowel disease (IBD) in patients with genetic syndromes. Methods: Multicenter observational case‐control study using data from the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition IBD registry. Patients diagnosed with pediatric‐onset IBD (p = 0.004) and height (−1.43 z ‐score, p < 0.001); these differences persisted at follow‐up. Diagnostic delay was longer in syndromic patients (+6.5 months, p = 0.045). Abdominal pain was less frequent at presentation ( p = 0.01). Syndromic patients had more hospitalizations (IBD‐related incidence rate ratio [IRR] 1.23, p = 0.033; non‐IBD IRR 1.65, p < 0.001), more comorbidities (odds ratio [OR] 18.2, p < 0.001), and greater use of non‐IBD medications (OR 8.17, p = 0.004). The risk of additional autoimmune diseases was higher but not statistically significant. Conclusions: Pediatric IBD patients with genetic syndromes show impaired growth and delayed diagnosis, while intestinal disease activity and treatment exposure are comparable to non‐syndromic peers. The higher burden of comorbidities and hospitalizations indicates greater healthcare complexity and diagnostic challenges; early recognition and coordinated multidisciplinary care are reasonable clinical considerations, but their impact on outcomes requires prospective evaluation.
- 17 September 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
Current practices and unmet needs in the management of Clostridioides difficile infection in pediatric inflammatory bowel disease: A national survey
Objectives: Children with inflammatory bowel disease (IBD) are at increased risk for Clostridioides difficile infection (CDI), which is associated with worse clinical outcomes. We aimed to assess current diagnostic and therapeutic practices for CDI among Italian pediatric IBD centers. Methods: A nationwide survey was conducted in 2025 using a structured 28‐item questionnaire distributed to all pediatric IBD centers in Italy. Items addressed diagnostic strategies, treatment approaches, recurrence management, and immunosuppressive therapy handling in children with IBD and CDI. Results: Twenty‐seven centers responded (response rate, 90%). Diagnostic approaches varied: toxin enzyme immunoassays (EIA) were indicated by 21/27 centers (78%), glutamate dehydrogenase (GDH) testing by 19/27 (70%), and nucleic acid amplification tests (NAAT) by 13/27 (48%). Routine CDI testing at IBD diagnosis was indicated by 12/27 centers (44%), whereas 23/27 (85%) reported testing during IBD flares. For a first non‐severe episode, vancomycin and metronidazole were equally identified as preferred first‐line options (18/27; 66% each). Oral vancomycin was the preferred treatment for recurrent CDI (26/27; 96%). Third or subsequent recurrences prompted consideration of fidaxomicin (19/27; 70%), fecal microbiota transplantation (6/27; 22%), and bezlotoxumab (2/27; 7%). In fulminant CDI, 7/27 centers (26%) indicated adding fidaxomicin to standard therapy. In acute severe colitis with concomitant CDI at diagnosis, 18/27 centers (67%) described a cautious approach to biologic initiation. Conclusions: This nationwide survey highlights substantial unmet needs in CDI management in pediatric IBD, including variability in diagnostic strategies, lack of consensus on first‐line therapy, and uncertainty regarding immunosuppressive management, supporting the need for evidence‐based pediatric‐specific guidelines.
- 17 September 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
Current practices and unmet needs in the management of Clostridioides difficile infection in pediatric inflammatory bowel disease: A national survey
Objectives: Children with inflammatory bowel disease (IBD) are at increased risk for Clostridioides difficile infection (CDI), which is associated with worse clinical outcomes. We aimed to assess current diagnostic and therapeutic practices for CDI among Italian pediatric IBD centers. Methods: A nationwide survey was conducted in 2025 using a structured 28‐item questionnaire distributed to all pediatric IBD centers in Italy. Items addressed diagnostic strategies, treatment approaches, recurrence management, and immunosuppressive therapy handling in children with IBD and CDI. Results: Twenty‐seven centers responded (response rate, 90%). Diagnostic approaches varied: toxin enzyme immunoassays (EIA) were indicated by 21/27 centers (78%), glutamate dehydrogenase (GDH) testing by 19/27 (70%), and nucleic acid amplification tests (NAAT) by 13/27 (48%). Routine CDI testing at IBD diagnosis was indicated by 12/27 centers (44%), whereas 23/27 (85%) reported testing during IBD flares. For a first non‐severe episode, vancomycin and metronidazole were equally identified as preferred first‐line options (18/27; 66% each). Oral vancomycin was the preferred treatment for recurrent CDI (26/27; 96%). Third or subsequent recurrences prompted consideration of fidaxomicin (19/27; 70%), fecal microbiota transplantation (6/27; 22%), and bezlotoxumab (2/27; 7%). In fulminant CDI, 7/27 centers (26%) indicated adding fidaxomicin to standard therapy. In acute severe colitis with concomitant CDI at diagnosis, 18/27 centers (67%) described a cautious approach to biologic initiation. Conclusions: This nationwide survey highlights substantial unmet needs in CDI management in pediatric IBD, including variability in diagnostic strategies, lack of consensus on first‐line therapy, and uncertainty regarding immunosuppressive management, supporting the need for evidence‐based pediatric‐specific guidelines.
- 22 July 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Disorders of Gut-Brain Interaction-Like Symptoms in Children With Inflammatory Bowel Disease: A Multicenter Prospective Study From the Pediatric Inflammatory Bowel Disease Porto Group of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition
INTRODUCTION: Disorders of gut-brain interaction (DGBI) are frequently reported in patients with inflammatory bowel disease (IBD), but pediatric data are scarce. We aimed to determine the prevalence of DGBI-like symptoms in children with quiescent IBD compared with healthy controls (HC), and to evaluate their impact on health-related quality of life, anxiety and symptoms burden. METHODS: This multicenter, prospective, observational study enrolled children aged 10–18 years with biochemically quiescent IBD, with or without endoscopic confirmation of remission from 7 European Society of Pediatric Gastroenterology, Hepatology and Nutrition centers (January 2021–August 2023). Age and sex-matched HC were recruited through primary care pediatricians and screened for subclinical inflammation using fecal calprotectin. DGBI were assessed using Rome IV criteria. Health-related quality of life and psychological burden were evaluated using IMPACT III, PROMIS Anxiety, Visceral Sensitivity Index–Child, and Behavioral Response Questionnaire–Child. RESULTS: A total of 253 children were enrolled (IBD: n = 131; HC: n = 122). The prevalence of DGBI-like symptoms did not differ between IBD and HC (34.4% vs 41.8%, P = 0.30). Functional abdominal pain disorders were present in 24.4% of children with IBD. Children with IBD and DGBI-like symptoms showed significantly lower IMPACT III scores compared with those without DGBI [median 74 (interquartile range 62.5–81) vs 84 (70–90); P = 0.001], with the greatest impairment in IBD symptoms, energy, and social domains. PROMIS Anxiety scores were higher in the DGBI group [31 (20–44) vs 21.5 (16–28); P < 0.001], with a greater proportion exceeding the clinical threshold (>50) (17.8% vs 3.5%; P = 0.008). Female sex was the only independent predictor of DGBI (OR 5.2, 95% CI 1.6–16.1; P = 0.005). DISCUSSION: DGBI-like symptoms are common in children with quiescent IBD and are associated with a substantial psychological and quality-of-life burden.
- 22 July 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Disorders of Gut-Brain Interaction-Like Symptoms in Children With Inflammatory Bowel Disease: A Multicenter Prospective Study From the Pediatric Inflammatory Bowel Disease Porto Group of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition
INTRODUCTION: Disorders of gut-brain interaction (DGBI) are frequently reported in patients with inflammatory bowel disease (IBD), but pediatric data are scarce. We aimed to determine the prevalence of DGBI-like symptoms in children with quiescent IBD compared with healthy controls (HC), and to evaluate their impact on health-related quality of life, anxiety and symptoms burden. METHODS: This multicenter, prospective, observational study enrolled children aged 10–18 years with biochemically quiescent IBD, with or without endoscopic confirmation of remission from 7 European Society of Pediatric Gastroenterology, Hepatology and Nutrition centers (January 2021–August 2023). Age and sex-matched HC were recruited through primary care pediatricians and screened for subclinical inflammation using fecal calprotectin. DGBI were assessed using Rome IV criteria. Health-related quality of life and psychological burden were evaluated using IMPACT III, PROMIS Anxiety, Visceral Sensitivity Index–Child, and Behavioral Response Questionnaire–Child. RESULTS: A total of 253 children were enrolled (IBD: n = 131; HC: n = 122). The prevalence of DGBI-like symptoms did not differ between IBD and HC (34.4% vs 41.8%, P = 0.30). Functional abdominal pain disorders were present in 24.4% of children with IBD. Children with IBD and DGBI-like symptoms showed significantly lower IMPACT III scores compared with those without DGBI [median 74 (interquartile range 62.5–81) vs 84 (70–90); P = 0.001], with the greatest impairment in IBD symptoms, energy, and social domains. PROMIS Anxiety scores were higher in the DGBI group [31 (20–44) vs 21.5 (16–28); P < 0.001], with a greater proportion exceeding the clinical threshold (>50) (17.8% vs 3.5%; P = 0.008). Female sex was the only independent predictor of DGBI (OR 5.2, 95% CI 1.6–16.1; P = 0.005). DISCUSSION: DGBI-like symptoms are common in children with quiescent IBD and are associated with a substantial psychological and quality-of-life burden.
- Open Access
- 23 February 2026
- Published by Elsevier in Digestive and Liver Disease
- Vol. 58 (5) , 630-637
Exploring novel biomarkers in pediatric ulcerative colitis: The role of Lipocalin-2, MMP-9, and MMP-9/LCN-2 complex
- 23 February 2026
- Published by Elsevier in Digestive and Liver Disease
- Vol. 58 (5) , 630-637
Open AccessExploring novel biomarkers in pediatric ulcerative colitis: The role of Lipocalin-2, MMP-9, and MMP-9/LCN-2 complex
- Open Access
- 3 December 2025
- Published by Elsevier in Digestive and Liver Disease
- Vol. 58 (1) , 82-87
Diagnostic accuracy of non-invasive tests for helicobacter pylori infection in children: A multicenter retrospective study by SIGENP
- 3 December 2025
- Published by Elsevier in Digestive and Liver Disease
- Vol. 58 (1) , 82-87
Open AccessDiagnostic accuracy of non-invasive tests for helicobacter pylori infection in children: A multicenter retrospective study by SIGENP
- 13 October 2025
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 81 (6) , 1520-1521
Response to Letter to the Editor: “Prevalence and trend of anemia in children with inflammatory bowel disease”
- 13 October 2025
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 81 (6) , 1520-1521
Response to Letter to the Editor: “Prevalence and trend of anemia in children with inflammatory bowel disease”
- 22 August 2025
- Published by Elsevier in Digestive and Liver Disease
- Vol. 57 (11) , 2121-2127
Is transmural healing better than mucosal healing in pediatric Crohn’s disease?
- 22 August 2025
- Published by Elsevier in Digestive and Liver Disease
- Vol. 57 (11) , 2121-2127
Is transmural healing better than mucosal healing in pediatric Crohn’s disease?
- Open Access
- 1 March 2021
- Published by Elsevier in Digestive and Liver Disease
- Vol. 53 (3) , 283-288
Impact of COVID-19 pandemic on the management of paediatric inflammatory bowel disease: An Italian multicentre study on behalf of the SIGENP IBD Group
- 1 March 2021
- Published by Elsevier in Digestive and Liver Disease
- Vol. 53 (3) , 283-288
Open AccessImpact of COVID-19 pandemic on the management of paediatric inflammatory bowel disease: An Italian multicentre study on behalf of the SIGENP IBD Group
- 23 June 2020
- Published by Springer Nature in Pediatric Drugs
- Vol. 22 (5) , 463-472
Treat-to-Target in Pediatric Inflammatory Bowel Disease: What Does the Evidence Say?
The traditional management of inflammatory bowel disease, based on treatment intensification guided by clinical activity alone, has been revised in the last 10 years and a treat-to-target approach has been proposed and is currently under evaluation as a disease-modifying strategy. Treat-to-target focuses on objective and scheduled measures to monitor intestinal damage, with consequent therapeutic adjustments in case of failure to achieve pre-defined targets. Identification of targets has been set out by the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) committee in 2015. Mucosal healing is universally accepted as the main target both in Crohn’s disease and ulcerative colitis, given its proven association with better long-term outcomes than clinical remission alone. Equally important is to ensure patients’ clinical remission and improve patient-reported outcomes. Transmural healing (for Crohn’s disease) and histological remission (for ulcerative colitis), listed as adjunctive targets, are likely to become primary targets in the near future. The ultimate goal of this approach is to modify the natural history of inflammatory bowel diseases by trying to block bowel damage progression, with interventions in the pre-clinical stage. In this review, we will discuss the current recommended therapeutic targets, as well as those that are considered adjunctive targets, with a focus on the limited pediatric literature available. Prospective long-term trials are warranted in order to identify the most appropriate target for the pediatric population and its specific issues. Identification of reliable predictors of disease course, outcome, and response to treatment will help to individually adapt each step of this monitoring algorithm and consequent therapeutic decision.
- 23 June 2020
- Published by Springer Nature in Pediatric Drugs
- Vol. 22 (5) , 463-472
Treat-to-Target in Pediatric Inflammatory Bowel Disease: What Does the Evidence Say?
The traditional management of inflammatory bowel disease, based on treatment intensification guided by clinical activity alone, has been revised in the last 10 years and a treat-to-target approach has been proposed and is currently under evaluation as a disease-modifying strategy. Treat-to-target focuses on objective and scheduled measures to monitor intestinal damage, with consequent therapeutic adjustments in case of failure to achieve pre-defined targets. Identification of targets has been set out by the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) committee in 2015. Mucosal healing is universally accepted as the main target both in Crohn’s disease and ulcerative colitis, given its proven association with better long-term outcomes than clinical remission alone. Equally important is to ensure patients’ clinical remission and improve patient-reported outcomes. Transmural healing (for Crohn’s disease) and histological remission (for ulcerative colitis), listed as adjunctive targets, are likely to become primary targets in the near future. The ultimate goal of this approach is to modify the natural history of inflammatory bowel diseases by trying to block bowel damage progression, with interventions in the pre-clinical stage. In this review, we will discuss the current recommended therapeutic targets, as well as those that are considered adjunctive targets, with a focus on the limited pediatric literature available. Prospective long-term trials are warranted in order to identify the most appropriate target for the pediatric population and its specific issues. Identification of reliable predictors of disease course, outcome, and response to treatment will help to individually adapt each step of this monitoring algorithm and consequent therapeutic decision.
- 3 May 2020
- Published by Taylor & Francis in Expert Review of Gastroenterology & Hepatology
- Vol. 14 (5) , 335-345
Mucosal healing in Crohn’s disease: new insights
Introduction. Traditional management of patients with Crohn’s disease includes symptoms and quality of life improvement. With the advent of biological agents, mucosal healing has become an achievable goal, documented through endoscopy. However, due to the transmural nature of inflammation, the prevention of bowel damage should be included in the aims of a targeted therapeutic strategy. Areas Covered. Updated literature has been searched in PubMed from 2008 to 2020. This review focuses on the state of the art in the innovative therapeutic goals in Crohn’s disease, also considering still controversial aspects and future research topics in the management of Crohn’s disease. Expert Opinion. Although a widely agreed view supports the notion that mucosal healing and bowel damage control may promote beneficial outcomes (i.e. reduction in hospitalization and surgical rates, avoidance of steroids), long term robust data are still missing. On the other hand, the development of -omics techniques have expanded our knowledge of the pathogenetic mechanism underlying inflammatory bowel disease and opened up new horizons in precision or personalized medicine.
- 3 May 2020
- Published by Taylor & Francis in Expert Review of Gastroenterology & Hepatology
- Vol. 14 (5) , 335-345
Mucosal healing in Crohn’s disease: new insights
Introduction. Traditional management of patients with Crohn’s disease includes symptoms and quality of life improvement. With the advent of biological agents, mucosal healing has become an achievable goal, documented through endoscopy. However, due to the transmural nature of inflammation, the prevention of bowel damage should be included in the aims of a targeted therapeutic strategy. Areas Covered. Updated literature has been searched in PubMed from 2008 to 2020. This review focuses on the state of the art in the innovative therapeutic goals in Crohn’s disease, also considering still controversial aspects and future research topics in the management of Crohn’s disease. Expert Opinion. Although a widely agreed view supports the notion that mucosal healing and bowel damage control may promote beneficial outcomes (i.e. reduction in hospitalization and surgical rates, avoidance of steroids), long term robust data are still missing. On the other hand, the development of -omics techniques have expanded our knowledge of the pathogenetic mechanism underlying inflammatory bowel disease and opened up new horizons in precision or personalized medicine.